Skip to Content
Merck
CN
  • T-bet is a key modulator of IL-23-driven pathogenic CD4(+) T cell responses in the intestine.

T-bet is a key modulator of IL-23-driven pathogenic CD4(+) T cell responses in the intestine.

Nature communications (2016-05-20)
Thomas Krausgruber, Chris Schiering, Krista Adelmann, Oliver J Harrison, Agnieszka Chomka, Claire Pearson, Philip P Ahern, Matthew Shale, Mohamed Oukka, Fiona Powrie
ABSTRACT

IL-23 is a key driver of pathogenic Th17 cell responses. It has been suggested that the transcription factor T-bet is required to facilitate IL-23-driven pathogenic effector functions; however, the precise role of T-bet in intestinal T cell responses remains elusive. Here, we show that T-bet expression by T cells is not required for the induction of colitis or the differentiation of pathogenic Th17 cells but modifies qualitative features of the IL-23-driven colitogenic response by negatively regulating IL-23R expression. Consequently, absence of T-bet leads to unrestrained Th17 cell differentiation and activation characterized by high amounts of IL-17A and IL-22. The combined increase in IL-17A/IL-22 results in enhanced epithelial cell activation and inhibition of either IL-17A or IL-22 leads to disease amelioration. Our study identifies T-bet as a key modulator of IL-23-driven colitogenic responses in the intestine and has important implications for understanding of heterogeneity among inflammatory bowel disease patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-15, ascites fluid